Nucleophosmin/B23 interacts with p21WAF1/CIP1 and contributes to its stability

Cell Cycle

Volumn 8, Issue 6, 2009, Pages 889-895

  Xiao, Jianyong ^a   Zhang, Zhiyi ^a   Chen, George Gong ^c   Zhang, Meifang ^a   Ding, Yuanjie ^a   Fu, Jia ^a   Li, Mingtao ^b   Yun, Jing Ping ^a,d  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Actinomycin D; Half life; Interaction; NPM B23; P21; Stability; Ubiquitination

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; DACTINOMYCIN; NUCLEOPHOSMIN; PROTEIN P21; SMALL INTERFERING RNA;

ARTICLE; CONFOCAL MICROSCOPY; DOWN REGULATION; EMBRYO; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TRANSPORT; UBIQUITINATION; UPREGULATION;

EID: 65349151239     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.6.7898     Document Type: Article

References (33)

1. Dotto GP. p21(WAF1/Cip1): More than a break to the cell cycle? Biochim Biophys Acta 2000; 1471:43-56.
2. Gartel AL, Tyner AL. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp Cell Res 1999; 246:280-9.
3. Child ES, Mann DJ. The intricacies of p21 phosphorylation: Protein/protein interactions, subcellular localization and stability. Cell Cycle 2006; 5:1313-9.
4. WAF1/CIP1 expression. Biochem Biophys Res Commun 1996; 227:564-9.
5. Cip1 ubiquitination. Mol Cell 2000; 5:403-10.
6. Bloom J, Pagano M. To be or not to be ubiquitinated? Cell Cycle 2004; 3:138-40.
7. Oh H, Mammucari C, Nenci A, Cabodi S, Cohen SN, Dotto GP. Negative regulation of cell growth and differentiation by TSG101 through association with p21(Cip1/WAF1). Proc Natl Acad Sci USA 2002; 99:5430-5.
8. Jascur T, Brickner H, Salles-Passador I, Barbier V, El Khissiin A, Smith B, et al. Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein. Mol Cell 2005; 17:237-49.
9. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56:379-90.
10. Takemura M, Sato K, Nishio M, Akiyama T, Umekawa H, Yoshida S. Nucleolar protein B23.1 binds to retinoblastoma protein and synergistically stimulates DNA polymerase alpha activity. J Biochem 1999; 125:904-9.
11. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, et al. Nucleophosmin/ B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000; 103:127-40.
12. Gao H, Jin S, Song Y, Fu M, Wang M, Liu Z, et al. B23 regulates GADD45a nuclear translocation and contributes to GADD45a-induced cell cycle G2-M arrest. J Biol Chem 2005; 280:10988-96.
13. Valdez BC, Perlaky L, Henning D, Saijo Y, Chan PK, Busch H. Identification of the nuclear and nucle olar localization signals of the protein p120. Interaction with translocation protein B23. J Biol Chem 1994; 269:23776-83.
14. Ochs R, Lischwe M, O'Leary P, Busch H. Localization of nucleolar phosphoproteins B23 and C23 during mitosis. Exp Cell Res 1983; 146:139-49.
15. Rubbi CP, Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J 2003; 22:6068-77.
16. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004; 24:985-96.
17. Kerr LE, Birse-Archbold JL, Short DM, McGregor AL, Heron I, Macdonald DC, et al. Nucleophosmin is a novel Bax chaperone that regulates apoptotic cell death. Oncogene 2007; 26:2554-62.
18. Szebeni A, Olson MO. Nucleolar protein B23 has molecular chaperone activities. Protein Sci 1999; 8:905-12.
19. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002; 4:529-33.
20. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6:493-505.
21. Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 2003; 115:71-82.
22. Waf1/Cip1/ Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. Proc Natl Acad Sci USA 1996; 93:11504-9.
23. Cayrol C, Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 1998; 17:2437-44.
24. Coleman ML, Marshall CJ, Olson MF. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J 2003; 22:2036-46.
25. waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J 2003; 22:6365-77.
26. Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2- mediated degradation. Cancer Cell 2004; 5:465-75.
27. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000; 20:3224-33.
28. Giono LE, Manfredi JJ. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest. Mol Cell Biol 2007; 27:4166-78.
29. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263-9.
30. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366:701-4.
31. Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, et al. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 1993; 8:2457-67.
32. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71:587-97.
33. Yun JP, Miao J, Chen GG, Tian QH, Zhang CQ, Xiang J, et al. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer 2007; 96:477-84.